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httpicense.Abstract Introduction: Behc¸et’s disease (BD) is an idiopathic multisystem disorder. Cardiac
involvement [cardio-BD] occurs in 7–60% of BD patients. Technetium 99m-Methoxyisobutyl iso-
nitrile (Tc-99m sestamibi) is a myocardial perfusion imaging agent that is used for evaluation of
the coronary ﬂow.
Aim of the work: To evaluate the usefulness of Dipyridamole pharmacological stress test in con-
junction with Tc-99m sestamibi cardiac gated single photon emission computed tomography
(GSPECT) to investigate the prevalence of subclinical coronary endothelial dysfunction [SCED]
in asymptomatic Egyptian BD patients; also to assess possibly associated clinical predictive vari-
ables.
Patients and Methods: Twenty-ﬁve BD patients without overt cardiac involvement and ﬁfteen
healthy controls matched for age, BMI and sex were included. Database included full history, clin-
ical examination, relevant laboratory tests, and Tc-99m sestamibi myocardial GSPECT with coro-
nary angiography [CAG] in GSPECT positive cases. Disease activity was assessed using Behc¸et’s
Disease Current Activity Form (BDCAF).2, Soliman Abaza St. Al-
1648583; fax: +20 233 44 45.
(A.M. Amin).
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160 A.M. Amin, Z.O. NawitoResults: SCED detected by reduced ﬂow or left ventricular dysfunction (LVD) or both was
found in 13/25 [52%] of BD-patients [12 males and 1 female] vs. 1/15 [6.7%] of controls
[P< 0.0001] with normal CAG. Subjects with positive GSPECT had signiﬁcantly older age
[P= 0.01] and longer disease duration (P= 0.02) and were more frequently males (P< 0.0001)
than those with negative GSPECT. No statistically signiﬁcant differences between cases with neg-
ative and positive GSPECT were found regarding other clinical or laboratory parameters.
Conclusion: Tc-99m sestamibi GSPECT could be a useful screening tool for detection of SCED
in BD patients, so early prophylactic measures and therapy modiﬁcations could be considered.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis. Open access under CC BY-NC-ND license.1. Introduction
Behc¸et’s disease (BD) is a generalized chronic inﬂammatory
disease characterized by a triad of recurrent oral aphthous le-
sions, genital ulcers and uveitis [1] however, involvement of
many other systems is also observed [2]. BD has a wide range
of effects on the cardiovascular system resulting in a variety
of clinical manifestations. Clinical reports showed cardiac
abnormalities in 7–60% of BD patients with mortality preva-
lence 20% greater in those with vascular involvement [3–6]
including pancarditis, coronary arteritis, acute myocardial
infarction, cardiomyopathy and even sudden cardiac death
[6]. Vasculitis, a key feature of the disease, may lead to func-
tional disturbances in highly vascularized organs including
the heart. Although coagulation disorders have also been re-
ported yet they cannot explain the different thrombotic mani-
festations which are probably the consequence of an
abnormal response of the vascular endothelial cells. Prompt
resolution of the symptoms provided by corticosteroid therapy
supports the conclusion of previous studies that myocardial
ischemia in BD may possibly be due to vasculitis of the coro-
nary arteries [7].
Cardiac involvement is considered as one of the most
important prognostic issues especially when considering the
fact that it might be asymptomatic [8]. The term silent
myocardial ischemia (SMI) in BD has been stated in three
previous reports [4,6,9] using radionuclide modality. However,
there are some limitations; the available three reports belong
only to the Turkish population, hence the need for further
studies about BD-induced coronary vascular dysfunction in
other communities along the silk route. Additionally, only
one report used Technetium-99m methoxyisobutylisonitrile
(Tc-99m sestamibi) cardiac gated single photon emission
computed tomography (GSPECT) [6]. The latter simulta-
neously allows the determination of myocardial perfusion, left
ventricular ejection fraction (LVEF), and assessment of wall
motion [4,10] with high quality images when compared to
thallium-201 [Tl-201] which is not ideal for functional assess-
ment and is more hazardous regarding the patients’ radiation
exposure [longer half life 73-h vs. 6-h for Tc-99m] with its
relatively higher cost, therefore many researchers preferred
Tc-99m sestamibi use [11–14].
This study was designed to evaluate the usefulness of Dipy-
ridamole pharmacological stress test in conjunction with Tech-
netium 99m-Methoxyisobutyl isonitrile (Tc-99m sestamibi)
GSPECT to screen the prevalence of subclinical coronary
endothelial dysfunction [SCED] in asymptomatic Egyptian
BD patients and to identify those at higher risk for the pres-
ence of such abnormalities.2. Patients and methods
2.1. Study population
The study was approved by the local ethics committee of
Cairo-University scientiﬁc review board and informed consent
was obtained from all subjects according to the Declaration of
Helsinki; as revised in 1983. It included twenty-ﬁve BD pa-
tients (6 females and 19 males, mean age 36.7 ± 9.3 years;
range 24–51) who were randomly selected among other BD pa-
tients attending the outpatient clinic of the Rheumatology
Department, Cairo University Hospitals during 12 months
consecutively. They all fulﬁlled the International Study Group
criteria for the classiﬁcation of BD [2]. Fifteen age, sex and
BMI matched healthy subjects with a mean age of
38.5 ± 8.2 years served as control group. All subjects had no
clinical evidence of cardiac ischemia or abnormal electrocar-
diograms (ECG). Subject selection was based on the exclusion
of any factors that would affect the coronary arterial circula-
tion as hyperlipidemia, hypertension, diabetes mellitus, family
history of cardio-vascular disease, BMI-based obesity, abnor-
mal renal sonography or kidney functions or history of smok-
ing. Routine biochemical analyses were done, after an
overnight fast, for all subjects together with complete lipid pro-
ﬁle [serum cholesterol, triglyceride, low-density lipoprotein
(LDL), and high-density lipoprotein (HDL)].
Behc¸et’s Disease Current Activity Form (BDCAF) [15] was
used to assess disease activity. Scoring was based on the history
of new clinical features present over the preceding 4 weeks prior
to assessment. BDCAF scores include oral and genital ulcera-
tion; skin, joint, and gastrointestinal involvement; presence of
fatigue and headache according to the duration of symptoms.
The presence or absence of large vessel involvement was docu-
mented. We considered eye activity present if there was a his-
tory of blurring of vision or if the eye was painful or red with
conﬁrmation by a thorough ophthalmological examination.
2.2. Myocardial GSPECT
Dipyridamole-pharmacological stress was used by giving intra-
venously over 4–6 min [0.56 mg/kg body-weight]. A mild in-
crease in heart rate and mild reduction in blood pressure
conﬁrm the drug’s pharmacologic effect with imaging after
15 min following dipyridamol infusion. 22–25mCi of Tc-99m
sestamibi was injected with continuous ECG and blood pres-
sure monitoring. The stress and rest phases were performed
in a 2-day protocol [within one week] with data acquisition
using a dual head gamma camera (Philips Axis). Patient
Table 1 Clinical manifestation of Behc¸et’s disease patients
(n= 25).
Clinical features Value
Oral ulcers 80%
Genital ulcers 76%
Skin lesions 64%
Arthralgia 44%
Arthritis 10%
Lower GIa 24%
Upper GIa 12%
Active eyeb 36%
Major vascular involvement 0%
BDCAFc 8.4 ± 4.02d
a Gastrointestinal symptoms.
b None was positive for papilledema.
c Behc¸et’s disease current activity form.
d Mean ± SD.
Table 2 Laboratory data of Behc¸et’s disease patients
(n= 25).
Laboratory data Range Mean ± SD
Hemoglobin (mg %) 9.2–14.1 11.7 ± 1.3
LDL (mg/dl) 61–186 129.3 ± 40.6
HDL (mg/dl) 30–55 35.1 ± 23.7
Triglycerides (mg/dl) 30–172 112.07 ± 52.7
Cholesterol (mg/dl) 68–230 172.2 ± 54.1
LDL: low-density lipoprotein, HDL: high-density lipoprotein.
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clockwise rotation; 128 · 128 Matrix; 64 views image/arc
(180, 45 right anterior oblique and 135 left posterior obli-
que). In reconstruction; Ramp ﬁlter and convolution ﬁlter
[Butterworth] with oblique angle reformatting [short axis, ver-
tical and horizontal long axes]. In GSPECT; ECG synchro-
nized data collection by R-wave trigger [8 Frames/cardiac
cycle] were applied. In the rest phase; imaging was performed
30–60 min after sestamibi administration.
Visual assessment of myocardial perfusion of Left ventricu-
lar [LV] walls was done for defects [MPD]. Assignment of the
17 myocardial segments to the territories of the left anterior
descending (LAD), right coronary artery (RCA), and the left
circumﬂex coronary artery (LCX) was used.
GSPECT functional assessment was based on left ventricu-
lar ejection fraction [LVEF], End-Diastolic and End-Systolic
volumes [EDV, ESV] [Normal LVEF, EDV, ESV values are
45–50%, up to 120 and 60 ml respectively]. LV-wall motion
[LV-WM] was assessed visually for motion abnormalities
[hypokinesia, akinesia or dyskinesia]. Abnormal quantitative
parameters or LV-WM either alone or in combination were
indicative of left ventricular dysfunction [LVD]. We classiﬁed
the study subjects into GSPECT negatives and positives
[SCED]. Stress induced stunning was considered when LVD
was detected in association with normal perfusion pattern.
SCED was diagnosed in positive GSPECT cases using the fol-
lowing criteria: [1] reduced blood ﬂow to any of the left ven-
tricular walls, [2] LVD or [3] both were found. Coronary
angiography [CAG] was done in all MPD positives using Jud-
kin’s technique. Stenoses of coronary vessels were coded
according to the American Heart Association Criteria [16].
Statistical analysis: The data were analyzed by statistical
package for the social science (SPSS) version 14. Continuous
data were presented as means ± standard deviations (SD),
while discrete data were shown as numbers and percentages.
Cross tabulation was utilized to describe the relations between
variables using the contingency coefﬁcient. Levene’s test (F-
test) for the equality of variances was used and t-test for testing
the differences between parametric data. Comparison between
non-parametric variables was performed using the Mann–
Whitney U-test. Signiﬁcance was deﬁned as P < 0.05
throughout.3. Results
3.1. Study population
Our 25 BD patients (19 males, 76%, and 6 females, 24%) had
mean disease duration of 5.75 year ± 3.6. Their clinical char-
acteristics are shown in Table 1. Twenty-two patients (88%)
were on oral prednisone (5–20 mg/day; mean, 10.4 ± 7.3)
and colchicine, 8 (32%) on IV cyclophosphamide pulses, 11
(44%) on azathioprine, 10 (40%) on oral anticoagulants, 2
(8%) on nonsteroidal anti-inﬂammatory drugs, 2 (8%) on
methotrexate (MTX), and one (4%) patient uses chlorambucil.
The laboratory data of the studied cases were within normal
limits including LDL, HDL, triglycerides, and serum choles-
terol and the comparison between the lipid proﬁle mean values
in BD and controls was not statistically signiﬁcant Table 2.
The mean BMI-values were (23.73 ± 2.62) and
(22.85 ± 3.61) in BD patients and controls respectively.3.2. Myocardial GSPECT Imaging and Coronary Angiography
Positive GSPECT was found in 13/25 BD patients (52%) with-
out ECG abnormalities [12/19 (63.2%) males and 1/6 (16.7%)
females; P< 0.0001] compared to 1/15 (6.7%) in the control
group being a male who had mild hypoperfusion in the ante-
rior wall (P< 0.0001) (Table 3; Fig. 1 and 2). Regarding re-
duced blood ﬂow to any of the left ventricular walls; it was
found in 12 BD cases where 9/12 (75%) and 3/12 (25%) BD
patients had mild and moderate stress induced hypoperfusion
denoting SCED in LAD (9 patients), RCA (5 patients) and
LCX (1 patient) vascular territories Table 3. Regarding
LVD; it was found in 11/25 BD patients compared to none
of the controls (P < 0.0001) Table 3. The 11/13 GSPECT pos-
itives had abnormal LV-WM [hypokinesia] with mildly re-
duced LVEF [contractile power] in only three of them;
however in one case stress-induced stunning [Abnormal reduc-
tion in stress LVEF that normalizes in the rest phase] was
found Table 4. CAG was done for the 13 GSPECT positives
and showed no coronary stenosis. The positive control subject
refused to undergo CAG.
3.3. Comparison between BD patients with normal and abnormal
myocardial GSPECT
Patients with abnormal positive GSPECT had signiﬁcantly
older age than those with negative GSPECT (46.7 years ± 5.3
vs. 31.7 ± 6.3) (P= 0.01) and were more frequently males (11
males vs. 1 female) (P < 0.001). No signiﬁcant difference was
elicited between the %LVEF stress means of positive or nega-
Figure 1 A 45-year-old female with Behc¸et’s disease of 2-year
duration, with stress induced mild reduced ﬂow at the inferior wall
[Arrowed] deducing vasculitis in RCA vascular territory with
complete recovery in the rest phase [Upper rows: short axis;
middle rows: long axis horizontal and lower row: long axis
horizontal] and normal wall motion and %LVEF [P60%].
Coronary angiography was unremarkable.
Table 3 Comparison of Gated-SPECT in Behc¸et’s disease
[BD] and control groups.
Myocardial Gated
SPECT No [%]
BD Group
[n. 25] %
Control Group
[n. 15] %
P Value
RP* Positive 12 [48] 1 [6.7] 0.0001
LVD** 11 [44] 0 [0] 0.0001
Total 13 [48] 1 [6.7] 0.0001
* RP: Reduced perfusion [coronary Flow].
** LVD: Left ventricular dysfunction [Abnormal Left ventricular
ejection fraction, volumes and wall motion].
162 A.M. Amin, Z.O. Nawitotive GSPECT BD cases (51.7 ± 9.4 vs. 53 ± 5.1 respectively).
A statistically signiﬁcant difference was found between both
groups regarding disease duration (7.3 years ± 2.1 in positive
vs. 3.2 ± 1.8 in negative) (P= 0.02), while no signiﬁcant dif-
ferences were found regarding BDCAF, frequency of active
eye disease, history of medication and other BD clinical
manifestations.
4. Discussion
This study was carried out on 25 Egyptian BD patients with-
out overt clinical cardiac ischemia and showed a high preva-
lence of subclinical coronary vascular dysfunction compared
to controls (13 vs. 1) as detected by Dipyridamole stress
GSPECT with no corresponding coronary stenoses in CAG.
As far as we are aware; no prior studies suggested pharmaco-
logical stress testing in conjunction with sestamibi GSPECT in
BD patients as a screening test for SCED in the coronary cir-
culation. Vascular endothelial dysfunction [VED] was detected
in the earliest stages of atherosclerosis [17–19] and its detection
is considered among the important prognostic factors in BD
patients [8].The diverse spectrum of cardiovascular involvement in BD
was recognized since 1946 and considered to be peculiar as it
occurs in young subjects with no vascular risk factors [21]. It
includes coronary artery disease which is often expressed by
myocardial infarction or angina with a relatively high mortal-
ity [20].
On the other hand, a healthy endothelium is a monolayer of
cells located between the blood and the underlying tissues that
plays an important role in the regulation of vascular tone, bal-
ance between effects of relaxing and contracting factors,
thrombosis, vascular inﬂammation, and smooth muscle cell
proliferation. VED is characterized by reduced vasodilation
which is also by itself a prothrombotic and proinﬂammatory
state and was found in essential hypertension, diabetes, coro-
nary heart disease, chronic renal failure [21–24], rheumatoid
arthritis and systemic lupus erythematosus [25]. The presence
of VED in BD patients was ﬁrst reported by Chambers et al.
study [26] and could be associated with reduced systemic ﬁbri-
nolytic activity that may lead to myocardial infarction or acute
coronary syndrome [27]. The presence of vasculitis may result
in signiﬁcant impairment of endothelial cell function in BD
with subsequently reduced endothelium-derived vasodilator
that could lead to vasoconstriction, platelet aggregation and
monocyte adhesion contributing to vascular disease [26].
Generally, macrovascular pathologies are recognized by
clinical history, physical examination, Doppler ultrasonogra-
phy and angiography while microvascular disorders may be
investigated by laser Doppler and capillary microscopy [28].
VED can be assessed by endothelium-dependent vasodilata-
tion measuring tests [21–24] which are based mainly on the
stimulation of endothelial nitric oxide release that could be
achieved either by infusion of vasoactive substances like acetyl-
choline or by inducing transient ischemia as in ﬂow-mediated
dilatation of the brachial artery where a pneumatic cuff is in-
ﬂated for 5-min over the forearm to cause arterial occlusion
[Transient ischemia] [24]. On the other hand, Dipyridamole
is an indirect coronary vasodilator that works by increasing
intravascular adenosine through inhibition of phosphodiester-
ase that prohibits reuptake of endogenously produced adeno-
sine into endothelial and red blood cells leading to arteriolar
vasodilatation. This increases coronary arterial ﬂow to
approximately three times of resting values in the healthy
endothelial state, however it is attenuated in diseased coronary
arteries that cannot further dilate in response to adenosine. So,
Dipyridamole infusion produces a relative ﬂow heterogeneity
throughout coronary arteries, resulting in relatively more cor-
onary blood ﬂow in healthy arteries compared with the dis-
eased-arteries as in vasculitis inducing ischemia via a
‘‘coronary steal phenomenon’’ with subsequent perfusion de-
fects [hypoperfusion] ± abnormal LV-WM during radionu-
clide imaging [29,30]. Hence, we used Dipyridamole stress in
conjunction with Tc-99m sestamibi GSPECT as a screening
tool for SCED of the coronary circulation in BD patients.
Asymptomatic myocardial ischemia in BD was documented
and deﬁned as SMI [4,31]; it was postulated that autonomic
nervous system dysfunction in BD patients [32] might be
responsible for its silence as neuropathic damage to the myo-
cardial sensory afferent ﬁbers in the autonomic nerve supply
reduces the individual’s sensitivity to ischemia by interrupting
pain transmission [4]. Thus, our study was conducted for
SCED screening of the coronaries in asymptomatic BD popu-
lation. Regarding their demographic characteristics; male/fe-
Figure 2 A 33-year-old control normal Case with normal GSPECT study [Upper rows: short axis; middle rows: long axis horizontal and
lower row: long axis horizontal] and normal wall motion and %LVEF [P65%].
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other similar studies [4,6]. However, their mean age
(36.7 ± 9.3 years) was comparable to that of previous reports
[4,6,9]. The reported increased frequency of male involvement
may be explained by the higher incidence of systemic compli-
cations and more severe disease in men, possibly bringing them
to earlier medical attention [33].
In the current study, no stress ECG changes were elicited in
the GSPECT positive cases. It was previously stated that even
if ECG was normal, GSPECT might be abnormal [34,35]. Gul-
lu et al. [9] reported SMI in 25% of BD patients vs. 2.6% in
controls using ambulatory ECG monitoring; 89% of them
had reversible perfusion defects by radionuclide imaging. Also,
Turkolmez et al. [4] showed ischemic changes in 19.5% of BD
patients compared to 2.9% in controls. However, in the afore-
mentioned two studies Thallium-201 (Tl-201) was used with-
out gated functional assessment while in our study we used
Dipyridamole stress Tc-99m sestamibi GSPECT with a higher
prevalence of SCED than in controls (52% vs. 6.7%). Ourﬁndings concur with Kaya et al. study [6] where coronary vas-
cular dysfunction was found in 13/23 (56.5%) of BD patients
vs. 2/10 of controls (10.0%). In our study, LAD was the most
frequently affected followed by RCA and LCX respectively
which is in agreement with other reports [6,9,36,37].
In the present study; LVD was found in 44% of BD pa-
tients vs. none of the controls with hypokinesia as the only
form of LV-WM abnormality mostly in the anterior wall
and this concurs with Kaya et al. and Gemici et al. studies
[6,31], however Kaya et al. investigated other functional
parameters that were not enrolled in our study. In one of
our BD patients ‘‘stunning’’ was detected which is a stress-
induced acute transient myocardial ischemia manifested by re-
duced LVEF and abnormal LV-WM with apparently normal
coronary ﬂow that persists for several hours but is eventually
followed by functional recovery [38]. Repetitive episodes of
stunning can be cumulative and lead to more prolonged
LVD and such abnormality is thought to be a causative mech-
anism for future cardiomyopathy and heart failure [38,39]. Be-
Table 4 Results of abnormal Tc-99m sestamibi GSPECT in BD Patients.
Patient No. Age* Sex GSPECT
Reduced Flow [SCED**] Left Ventricular Dysfunction
Aﬀected wall Hypoperfusion Grade Corresponding
vascular territory
EDVa[ml] ESVb[ml] %LVEFc Wall Motion
Abnormalities
[hypokinesia]
Stress Rest Stress Rest Stress Rest
1 49 M Apex and anterior Mild LADd 90 75 40 35 55% 53% Mild
2 48 M Anterior, anteroseptal Mild LAD 80 65 35 30 56% 54% Mild
3 47 M Apex and anterior Mild LAD 93 75 35 32 54% 57% Mild
4 46 M Anterior and inferior Mild LAD & RCAe 77 60 35 30 55% 50% Mild
5 44 F Inferior Mild RCA 66 55 23 20 65% 63% None
6 48 M Anterior, anteroseptal Mild LAD 89 67 43 33 51% 51% Mild
7 49 M Apex and anterior Mild LAD 76 62 30 26 61% 56% Mild
8 47 M Anterior Moderate LAD 140 125 78 72 44% 43% Moderate
9 39 M Apex and anterior Mild LAD 89 75 41 37 54% 51% Mild
10 45 M Inferior Mild RCA 84 59 32 25 62% 58% None
11 49 M Anterior and inferior Moderate LAD and RCA 115 102 65 60 44% 44% Moderate
12 49 M Apex, anterior, inferior and lateral Moderate LAD, RCA and LCXf 140 130 92 82 44% 45% Moderate
13*** 49 M None No perfusion abnormalities None 133 120 82 60 38% 50% Severe
a EDV: End diastolic volume.
b ESV: End systolic volume.
c LVEF: Left ventricular ejection fraction.
d LAD: Left anterior descending.
e RCA: Right coronary artery.
f LCX: Left circumﬂex.
* M/F ratio 11:1 [P> 0.0001].
** SCED: sub-clinical coronary endothelial dysfunction.
*** Positive stunning.
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nomenon in BD patients.
CAG showed no signiﬁcant coronary stenoses in BD pa-
tients with positive GSPECT in the current study. Concordant
outcomes were reported in similar studies; where none of the
BD population in Tu¨rko¨lmez et al. study [4] showed CAG
abnormalities, while vast majority of the BD positives in Kaya
et al. and Gu¨llu¨ et al. studies were CAG negative [6,9]. Kosar
et al. reported acute MI in a young BD male patient diagnosed
by ECG with normal CAG [27]. This non concordance be-
tween CAG and radionuclide imaging may be explained as
the latter delineates the subclinical impairment in coronary
microcirculation and altered coronary vasomotor activity sec-
ondary to endothelial dysfunction on top of vasculitis, while
CAG shows only macrovascular abnormalities [4,9,40].
No signiﬁcant difference was found between positive and
negative Gated-SPECT cases regarding BD clinical parame-
ters, except for age, gender and disease duration. SCED was
detected in older ages and longer disease duration; this agrees
with other reports [4,6,9] and Ugurlu et al. questionnaire [41],
who assessed the prevalence of angina and ischemic heart dis-
ease in BD and stated that affected patients were more likely to
be older and hypertensive and less likely to smoke while the
rest of atherosclerotic risk factors were similar between pa-
tients and controls. The same applies for the male predomi-
nance in GSPECT positives cases as the male/female ratio
was 3:1 as in Tu¨rko¨lmez et al. and Kaya et al. studies [4,6]. Be-
sides, the medication history showed no signiﬁcant difference
between the BD GSPECT positive and negative cases; and this
agrees with earlier studies [4,6].
Finally, our main limitation is the small sample size [both
patients and controls], however our main strength is the sug-
gestion of cardiac assessment by using Dipyridamole stress
in conjunction with Tc-99m sestamibi GSPECT. Such a meth-
odology can display reduced coronary ﬂow and LVD at an
early stage of BD providing a better understanding of hemocir-
culatory and metabolic features of the illness. Also, it can al-
low the monitoring of patient’s clinical condition and
possibly treatment response. It is evident that SCED in BD
must be diagnosed precociously; GSPECT as a complementary
modality can be of great help that may omit the need for CAG,
and even when being normal, it can exclude the presence of ac-
tive coronary vasculitis.
It might be concluded that dipyridamole stress GSPECT
myocardial perfusion imaging can be effectively used to diag-
nose preclinical coronary vascular endothelial dysfunction in
Behc¸et’s disease and might be utilized for evaluating cardiac
involvement as a mirror image of active coronary vasculitis.
We believe it has a place as a screening tool for SCED consid-
ering the fact; whenever the diagnosis, the better is the result.References
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